CRMD CorMedix Inc.

-0.37  -4%
Previous Close 8.95
Open 9
Price To Book 12.44
Market Cap 204,326,342
Shares 23,814,259
Volume 591,075
Short Ratio 8.12
Av. Daily Volume 439,634

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released January 2019. Noted July 9, 2019 that following discussions with the FDA, further trials are not currently required.
Neutrolin - LOCK-IT 100
Hemodialysis patients with central venous catheters
Phase 3 to be initiated pending funding.
Neutrolin - LOCK-IT 200
Oncology patients on Total Parental Nutrition (TPN)

Latest News

  1. Why CorMedix Shares Are Rallying
  2. CorMedix Receives Encouraging FDA Feedback on Neutrolin® LOCK-IT-100 Data
  3. CorMedix Announces Publication of Taurolidine Pre-Clinical Oncology Data in “Investigational New Drugs” Journal
  4. 18 Stocks Joining The Russell Indices
  5. CorMedix Inc. Set to Join the Russell 2000® Index
  6. Edited Transcript of CRMD earnings conference call or presentation 13-May-19 8:30pm GMT
  7. CorMedix Inc. to Ring NYSE Closing Bell on Monday, June 10
  8. CorMedix Inc. to Present at the 20th Annual B. Riley FBR Institutional Investor Conference
  9. CorMedix (CRMD) Reports Q1 Loss, Tops Revenue Estimates
  10. CorMedix: 1Q Earnings Snapshot
  11. CorMedix Inc. Reports First Quarter 2019 Financial Results and Provides Business Update
  12. Cormedix Announces Presentation of LOCK-IT-100 Study Results at National Kidney Foundation Spring 2019 Meeting
  13. Should You Take Comfort From Insider Transactions At CorMedix, Inc. (NYSEMKT:CRMD)?
  14. CorMedix Inc. to Report First Quarter 2019 Financial Results and Provide a Corporate Update on May 13
  15. CorMedix Announces Online Pre-Clinical Abstract at the Upcoming Annual Meeting of American Society of Clinical Oncology
  16. CorMedix Completes Sale of $5.4 Million of NOL Tax Benefits Through New Jersey Economic Development Authority Program
  17. CorMedix Notified of Compliance with NYSE American Listing Requirements
  18. Is CorMedix, Inc. (NYSEMKT:CRMD) Overpaying Its CEO?
  19. The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs
  20. CorMedix Confirms Previously Announced One-For-Five Reverse Stock Split